Program
rilzabrutinib
Also written as “Rilzabrutinib”, “rilzabrutinib SAR444671” and “Rilzabrutinib dose 1”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Hemolytic, Autoimmune · Immunoglobulin G4-Related Disease · Pemphigus · Common Variable Immunodeficiency, led by Sanofi.
Drug pageRilzabrutinib: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 2311 open or running | phase 3since Nov 29, 2018 | Feb 24, 2016 | Nov 25, 2026phase 3 · NCT07216079 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Feb 24, 2016 to Sep 18, 2020.
- Jun 9, 2019Named rilzabrutinibINNProposed as its International Nonproprietary Name in WHO's List 121
- Feb 3, 2021Phase 1 study in Healthy VolunteersNCT04748926 · 24 enrolled · Australia
- Aug 5, 20212 phase 2 studiesNCT05002777, NCT05018806
- Oct 17, 20212 phase 2 studiesNCT05104892, NCT05107115
- Mar 18, 2024Phase 1 study in Autoimmune DiseasesNCT06342700 · 28 enrolled · United States
- May 30, 20242 phase 1 studiesNCT06444204, NCT06444191
- Jul 8, 2024Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702 · 84 planned · United States, Argentina, Australia and more
- May 8, 20252 phase 3 studiesNCT06975865, NCT07007962
- May 14, 2025Phase 2 study in Graves DiseaseNCT06984627 · 30 planned · Argentina, Canada, Chile and more
- Jul 17, 2025Phase 3 study in Anemia, Hemolytic, AutoimmuneNCT07086976 · 90 planned · United States, Argentina, Austria and more
- Sep 17, 2025Phase 3 study in Immunoglobulin G4-Related DiseaseNCT07190196 · 124 planned · United States, Argentina, Belgium and more
- Oct 9, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07216079 · 3 enrolled · Japan
- Sep 21, 20262 phase 1 studiesNCT07855250, NCT07853131
- Oct 1, 2026Primary completion moved from 2026-08-25 to 2027-02-11Date moved laterphase 2 · +6 months · NCT06984627
- Oct 28, 2026Phase 3 study in Common Variable ImmunodeficiencyNCT07923305 · 96 planned
Ahead
- Nov 3, 2026Primary completion: phase 1 study in Healthy VolunteerNCT07855250
- Nov 25, 2026Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07216079
- Dec 23, 2026Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702
- Feb 11, 2027Primary completion: phase 2 study in Graves DiseaseNCT06984627
TargetBeta
“An orally bioavailable reversible covalent inhibitor of Bruton's tyrosine kinase (BTK), ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923305Common Variable Immunodeficiency | 3 | Not yet recruiting | May 10, 2035 | 96 |
| NCT07853131Renal Insufficiency · United States | 1 | Recruiting | Apr 21, 2027 | 16 |
| NCT07855250Healthy Volunteer · Canada | 1 | Active, not recruiting | Nov 3, 2026 | 14 |
| NCT07216079Purpura, Thrombocytopenic, Idiopathic · Japan | 3 | Active, not recruiting | Nov 25, 2026 | 3 |
| NCT07190196Immunoglobulin G4-Related Disease · United States, Argentina, Belgium and more | 3 | Recruiting | Jun 28, 2028 | 124 |
| NCT07086976Anemia, Hemolytic, Autoimmune · United States, Argentina, Austria and more | 3 | Recruiting | May 31, 2028 | 90 |
| NCT07007962Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Czechia and more | 3 | Recruiting | Nov 5, 2027 | 60 |
| NCT06984627Graves Disease · Argentina, Canada, Chile and more | 2 | Recruiting | Feb 11, 2027 | 30 |
| NCT06975865Anemia, Sickle Cell · United States, Belgium, Brazil and more | 3 | Recruiting | Jul 23, 2027 | 192 |
| NCT06500702Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more | 2 | Recruiting | Dec 23, 2026 | 84 |
| NCT06444204Liver Diseases · United States | 1 | Completed | Mar 23, 2021 | 29 |
| NCT06444191Healthy Volunteers · United States | 1 | Completed | Apr 12, 2021 | 23 |
| NCT06342700Autoimmune Diseases · United States | 1 | Completed | Apr 23, 2024 | 28 |
| NCT05107115Chronic Urticaria · Argentina, Canada, Chile and more | 2 | Completed | Jul 19, 2023 | 160 |
| NCT05104892Asthma · Argentina, Bulgaria, Canada and more | 2 | Completed | Feb 6, 2024 | 196 |
| NCT05018806Dermatitis, Atopic · United States, Canada, Chile and more | 2 | Completed | Jun 23, 2023 | 124 |
| NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Austria, China and more | 2 | Active, not recruiting | May 23, 2024 | 22 |
| NCT04748926Healthy Volunteers · Australia | 1 | Completed | May 21, 2021 | 24 |
| NCT04562766Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Completed | Jan 15, 2025 | 232 |
| NCT04520451Immunoglobulin G4-Related Disease · United States, Canada, France and more | 2 | Completed | Oct 15, 2024 | 27 |
| NCT03762265Pemphigus · United States, Argentina, Australia and more | 3 | Terminated | Jul 30, 2021 | 131 |
| NCT03395210Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Bulgaria and more | 2 | Completed | Jan 31, 2023 | 86 |
| NCT02704429Pemphigus · Australia, Croatia, France and more | 2 | Completed | Dec 18, 2019 | 42 |
How it is read
Names in the registry
- “Rilzabrutinib”, 10 entries
- “rilzabrutinib”, 9 entries
- “rilzabrutinib SAR444671”, 3 entries
- “Rilzabrutinib dose 1”, 1 entry
- “Rilzabrutinib dose 2”, 1 entry
Codes read as this program: SAR444671.
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 4 studies
- Anemia, Hemolytic, Autoimmune, 2 studies
- Immunoglobulin G4-Related Disease, 2 studies
- Pemphigus, 2 studies
- Common Variable Immunodeficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.